Bli medlem
Bli medlem

Du är här

2021-07-22

Episurf: European multicentre study initiated for 5 years' follow-up of Episealer® Talus patients

Episurf Medical (Nasdaq: EPIS B) today announces the initiation of a prospective investigator-initiated European multicentre study with 5 years' follow-up of 25 Episealer® Talus patients. The study is initiated by Prof. Niek van Dijk from FIFA Medical Center of Excellence, Madrid, Spain and surgeries will be performed in a number of European countries. The patients in the study will be followed up over 5 years with the subjective outcome measures VAS pain score, Foot and Ankle Outcome Score (FAOS) and EQ-5D-5L which is an instrument used for evaluation of life quality. Interim results from 2 years' follow-up are scheduled to be submitted for publication. The first clinic to enroll patients in the study is Arcademy Clinic at Sophiahemmet, Stockholm, Sweden, lead of MD, PhD Jouko Kivioja who was also the first Episealer® Talus user in Scandinavia. Episealer® Talus is Episurf Medical's CE marked joint implant intended for treatment of osteochondral ankle lesions. 

"I am pleased with this study design and it is important to gather clinical data for this promising technology", says Prof. Niek van Dijk.

"Robust clinical evidence is very important for us at Episurf and we are happy that a user group lead by Prof. Niek van Dijk decided to take this initiative", says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.